High accuracy seen even in individuals without cognitive impairment<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Dec. 11, 2025 (HealthDay News) — Plasma phosphorylated tau 217 (p-tau217) can reliably detect Alzheimer disease (AD) pathology in the preclinical stage, according to a meta-analysis published online Dec. 1 in JAMA Neurology<\/em>.<\/p>\n Michael Malek-Ahmadi, Ph.D., from the University of Arizona College of Medicine-Phoenix, and colleagues conducted a systematic literature review to identify published studies that compared amyloid-positive and amyloid-negative older adults without cognitive impairment. A meta-analysis was conducted to assess the standardized effect size of mean differences and classification accuracy of p-tau217.<\/p>\n Based on 18 studies (7,834 participants), the researchers found that a large effect size was observed for p-tau217 (Hedges g\u2009=\u20091.50). Values for p-tau217 also showed high accuracy for identifying amyloid-positive individuals without cognitive impairment (pooled area under the curve, 0.87).<\/p>\n “These findings demonstrate that plasma p-tau217 can reliably detect AD pathology in the preclinical stage,” the authors write. “These findings support the clinical utility of plasma p-tau217 as a scalable, minimally invasive tool for early identification of AD, particularly in settings where timely intervention with disease-modifying therapies may offer the greatest benefit in slowing or preventing disease progression.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n